FDA Warns of Reduced Effectiveness in Recalled Batches of Tydemy Birth Control Pills
August 03, 2023: The U.S. Food and Drug Administration (FDA) has issued a warning regarding sure lots of Tydemy birth control pills, which may have reduced effectiveness due to decreased levels of a critical ingredient in the product. The manufacturer, Lupin Pharmaceuticals, voluntarily recalled two batches of the oral contraceptive after one lot tested low for ascorbic acid and high for a known impurity. Inadequate ascorbic acid could potentially impact the effectiveness of birth control, leading to unexpected pregnancies.
Despite no reported adverse effects related to the recalled lots of Tydemy to date, it is essential for individuals using this birth control to check their stock and contact their healthcare provider if needed. The recalled Tydemy lots were distributed across the U.S. between June 2022 and May 2023, and their lot codes can identify them: L200183 and L201560, with expiration dates of January 2024 and September 2024, respectively.
Lupin Pharmaceuticals advises patients to continue taking their medication but to consult their healthcare provider immediately for advice on alternative contraceptive methods if the recall impacted their birth control or if they experience any problems taking the product.
The company also notifies wholesalers, distributors, pharmacies, and retailers, arranging to return all impacted products. Contact information can be found on the recall notice for those seeking reimbursement.
Key Actional Takeaways:
- If you use Tydemy birth control pills, check your stock to see if it falls under the recalled batches (lot codes L200183 and L201560).
- If the recall impacted your birth control, contact your healthcare provider immediately for advice on alternative contraceptive methods.
- Lupin Pharmaceuticals is arranging for the return of the recalled products, and reimbursement information can be found on the recall notice.
It’s essential for individuals using Tydemy birth control pills to take appropriate action and consult with healthcare providers to ensure effective contraceptive measures are in place. As Lupin Pharmaceuticals addresses the recall and the FDA closely monitors the situation, the safety and well-being of consumers remain a top priority.
